Recent Updates
Recently added Catalysts
HROW Positive Sentiment Score: 60/100

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Key Takeaway: Harrow (Nasdaq: HROW) will report its financial results for the third quarter of 2025 on November 10, 2025, following the market close. This announcement includes a conference call scheduled for November 11, 2025, to offer a business update. Harrow specializes in ophthalmic disease management and is focused on delivering accessible and effective medications for various ocular conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Harrow is preparing to report financial results, indicating growth and activity.
  • The company is committed to improving clinical outcomes and patient compliance.
  • Harrow provides a comprehensive portfolio addressing various eye diseases.

Full Press Release Details

NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, November 11, 2025, to discuss the results and provide a business update.
Conference Call Information
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com.
VP of Investor Relations & Communications

Frequently Asked Questions

When will Harrow announce its Q3 financial results?

Harrow will report its Q3 financial results on November 10, 2025, after market close.

How can I access the Harrow conference call?

You can access the live webcast on the 'Investors' page of Harrow’s website.

What areas does Harrow focus on in ophthalmic solutions?

Harrow provides solutions for conditions like dry eye, glaucoma, cataracts, and more.

Is there a replay of the conference call available?

Yes, a replay of the webcast will be available for one year on Harrow’s website.

Who should I contact for investor relations at Harrow?

You can contact the VP of Investor Relations via email at mbiega@harrowinc.com.

Last updated: Oct 27, 2025